But the findings are still beneficial, as evidence shows people who receive treatment for HIV do better with single-tablet, once-daily dosing, said Dr. Daliah Mehdi, chief clinical officer with the AIDS Foundation of Chicago.
"People are more likely to take their medications as prescribed and not miss doses, they are more satisfied with their treatment, and their virus is more likely to be kept under control," Mehdi said. "This all means that the one-pill-once-a-day regimens allow people with HIV to live longer, healthier lives and also makes them less likely to transmit the virus to others."
Ultimately, the regimen can improve a patient's outcome and perhaps reduce the risk of spreading HIV by reducing the amount of HIV in infected individuals.
"The medications contained in the Quad may or may not be better, but giving people one more single-tablet option is likely to result in better adherence and therefore better outcomes for those who can take the Quad," said Mehdi. "Yes, we do already have two single-tablet options, but they are not suitable for everyone. This gives us one more option, another opportunity for people to get on the simplest possible treatment regimen."
And those options have contributed to DeLorenzo's new life. Now interning at a multinational law firm, he encouraged to get diagnosed and seek treatment.
"People who have been what I've been through feel like they don't have a lief left," he said. "But they do and I'm proof of that."